KN
Kane Biotech Inc.
KNBIF · OTC
$0.02 +0.00% (+$0.00)
1M +17.30%
Market Cap $6.23M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 161.80x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 45.69%
EPS growth N/A
FCF growth N/A
Profitability
0 /100
Weak Gross margin 505.99%
Net margin 7,022.61%
Op. margin 8,162.01%
Quality
0 /100
Poor ROIC 312.41%
ROA 121.24%
Asset turnover 0.02x
Debt
6 /100
High Current ratio 0.61x
Int. coverage -17.23x
Debt/Equity N/A
Stability
32 /100
Unstable Beta 0.31x
Rev. volatility 798.91%
EPS volatility 22.98%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na KNBIF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Huizinga
Employees
20
Headquarters
Winnipeg
Nadcházející události
26 LIS
Earnings
Upcoming earnings report